ArticleCureus2025
Radiotherapy for Orbital Myeloid Sarcoma as Extramedullary Relapse in a Pediatric Acute Myeloid Leukemia Patient Post-haploidentical Bone Marrow Transplantation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Ablation as novel x therapy in the regimen for frail hematological malignancies with extramedullary lesion.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proliferation of immature granulocytic cells characterizes myeloid sarcoma (MS), which can be a rare extramedullary manifestation of acute myeloid leukemia (AML). MS can occur as an isolated lesion, concurrently with AML, or as a post-treatment relapse. In this case report, we describe a 12-year-old male with high-risk AML who underwent chemotherapy followed by haploidentical hematopoietic stem cell transplantation (HSCT). Two years post-HSCT, he experienced a relapse with testicular MS, requiring orchiectomy and radiation therapy. One year later, he experienced a second relapse, with the disease isolated to the left orbit without evidence of systemic disease. Given his prior treatments, chronic graft-versus-host disease, and negative minimal residual disease, radiation therapy alone (2,400 cGy in 12 fractions) was selected to treat the left orbital MS. The dosimetric analysis showed optimal tumor coverage while sparing critical structures. He achieved a complete clinical response with preserved vision. This case highlights the complexities of managing post-HSCT MS in pediatric patients and highlights the role of targeted radiation in localized relapse when systemic therapy is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.